Navigating the PMA Diagnostic Journey: Tests and Results
At a Glance
PMA is diagnosed through a neurological exam, EMG and nerve conduction studies, MRI scans, and sometimes genetic testing. The goal is to identify lower motor neuron changes, rule out treatable conditions that look similar, and monitor for new signs over time.
The diagnostic process for Progressive Muscular Atrophy (PMA) is often described as a “diagnosis of exclusion.” Because there is no single blood test that says “you have PMA,” doctors use a combination of electrical testing, imaging, and genetic screening to confirm the disease and—most importantly—rule out treatable conditions [1].
The Role of EMG: Your Electrical “Map”
The most important tool for evaluating your lower motor neurons is Electromyography (EMG) combined with Nerve Conduction Studies (NCS). Think of this as an electrical map of your body’s wiring.
- Nerve Conduction Study (NCS): This test checks how well and how fast your peripheral nerves send signals. In PMA, your sensory nerves (the ones that feel touch and pain) should typically function normally [2]. If they don’t, it might point toward a different type of neuropathy [3].
- Needle EMG: Your doctor will insert a tiny needle into various muscles to record their electrical activity. They are looking for two specific signs of lower motor neuron dysfunction:
- Active Denervation: This indicates that muscle fibers have lost their nerve supply. It appears on the monitor as fibrillations or positive sharp waves—spontaneous electrical activity from unstable muscle fibers [4][5].
- Chronic Reinnervation: This shows that your body is attempting to compensate. Nearby healthy nerves can grow new branches to take over for the damaged ones, creating larger-than-normal electrical signals called neurogenic motor units [6].
Importantly, an EMG only evaluates lower motor neurons and peripheral nerves. It cannot detect upper motor neuron damage in the brain. Upper motor neuron involvement is assessed primarily through your doctor’s physical neurological examination [7].
MRI: Looking for Structural Mimics
Magnetic Resonance Imaging (MRI) of the brain and spine is not used to “see” PMA directly. Instead, it is used to ensure nothing else is causing your symptoms [1].
- Cervical Spine MRI: This is used to rule out cervical myelopathy (pressure on the spinal cord in the neck) or a tumor, which can cause muscle wasting in the hands that looks identical to a motor neuron disease [8][9].
- Brain MRI: This helps rule out strokes, tumors, or other inflammatory brain diseases. While some specialized research MRIs can show signs of motor system changes, they are not routine diagnostic tests for PMA [1][9].
Genetic Testing: Understanding the Link
While the vast majority of PMA cases are “sporadic” (occurring by chance without a known family history), a small percentage of cases have a genetic cause [10]. These cases often overlap with the genes implicated in ALS:
- SOD1 and C9orf72: These are among the genes linked to ALS and sometimes found in PMA [11][10].
- SMN1: Testing for this gene helps rule out Spinal Muscular Atrophy (SMA), an inherited condition that mimics the lower motor neuron signs of PMA [12][13].
Your doctor may refer you to a genetic counselor to discuss the emotional, familial, and insurance implications of testing, and to help you decide which tests are appropriate. It is also important to know that a negative genetic panel does not entirely rule out an inherited component [14][11].
The Road Ahead: Monitoring and Follow-Up
Because a purely lower motor neuron syndrome can evolve over time, close monitoring is essential. Many specialized ALS and Neuromuscular clinics offer appointments every three months, though this cadence should be individualized based on your symptoms [15]. During these visits, your team will:
- Monitor Strength and Function: Tracking your daily activities and mobility [16].
- Respiratory Testing: Checking your breathing muscles to ensure you receive timely support [16].
- Repeat Exams: Performing neurological exams to look for any emerging upper motor neuron signs (like spasticity or brisk reflexes) [1][7].
- Cognitive Screening: Because there is an overlap between motor neuron diseases and cognitive/behavioral changes, screening tools like the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) may be offered to identify if you need extra support in managing daily routines [17][15].
If you experience sudden changes in your breathing, swallowing, or strength between scheduled visits, do not wait for your next appointment—contact your care team promptly [18].
Common questions in this guide
How is progressive muscular atrophy diagnosed if there is no single test?
What can EMG and nerve conduction studies show in PMA?
Why might I need a brain or cervical spine MRI for suspected PMA?
When is genetic testing considered for PMA?
What does follow-up monitoring involve after a PMA evaluation?
Which changes should prompt me to contact my care team before my next visit?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Progressive muscular atrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How many body regions currently show lower motor neuron signs on my EMG?
- 2.Do my EMG results show signs of 'active denervation' or 'chronic reinnervation' in muscles that I haven't noticed weakness in yet?
- 3.Was my MRI specifically looking for structural mimics like cervical myelopathy or nerve compression?
- 4.Given my family history and current symptoms, would meeting with a genetic counselor be appropriate to discuss testing for genes like C9orf72, SOD1, or SMN1?
- 5.During my physical exams, are you seeing any upper motor neuron signs that might change my diagnosis?
References
References (18)
- 1
[Motor neuron diseases from a radiological perspective : Focus on amyotrophic lateral sclerosis].
Warmann S
Radiologie (Heidelberg, Germany) 2026; (66(4)):272-277 doi:10.1007/s00117-026-01577-8.
PMID: 41714394 - 2
Motor neuropathies and lower motor neuron syndromes.
Verschueren A
Revue neurologique 2017; (173(5)):320-325 doi:10.1016/j.neurol.2017.03.018.
PMID: 28434507 - 3
Characteristics of Sensory Neuron Dysfunction in Amyotrophic Lateral Sclerosis (ALS): Potential for ALS Therapy.
Seki S, Kitaoka Y, Kawata S, et al.
Biomedicines 2023; (11(11)) doi:10.3390/biomedicines11112967.
PMID: 38001967 - 4
Awaji criteria for the diagnosis of amyotrophic lateral sclerosis in Hanoi, Vietnam.
Van Nguyen T, Tran TA, Vu HT
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(1)):393-398 doi:10.1007/s10072-021-05333-9.
PMID: 34023955 - 5
Amyotrophic lateral sclerosis or not: Keys for the diagnosis.
Lenglet T, Camdessanché JP
Revue neurologique 2017; (173(5)):280-287 doi:10.1016/j.neurol.2017.04.003.
PMID: 28461025 - 6
[Electrodiagnostic support in an atypical form of amyotrophic lateral sclerosis (Vulpian-Bernhardt syndrome)].
Aguilar-Vázquez CA, Aguilar-Castillo SJ, Raymundo-Carrillo AD
Revista medica del Instituto Mexicano del Seguro Social 2024; (62(1)):1-8.
PMID: 39116263 - 7
Progressive Muscular Atrophy.
Liewluck T, Saperstein DS
Neurologic clinics 2015; (33(4)):761-73.
PMID: 26515620 - 8
Amyotrophic lateral sclerosis and degenerative cervical myelopathy: phenotype-based diagnostic pitfalls, investigative mismatch, and practical clinical reasoning.
Chen D, Shen T, Ren H, Qiu P
Frontiers in neurology 2026; (17()):1901811 doi:10.3389/fneur.2026.1901811.
PMID: 42625715 - 9
Motor Neuron Diseases and Central Nervous System Tractopathies: Clinical-Radiologic Correlation and Diagnostic Approach.
Desai AB, Agarwal A, Mohamed AS, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(1)):e240067 doi:10.1148/rg.240067.
PMID: 39636751 - 10
An SPG7 mutation as a novel cause of monogenic progressive muscular atrophy.
Pereira Â, Tkachenko N, Fortuna AM, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(9)):3303-3305 doi:10.1007/s10072-023-06867-w.
PMID: 37213040 - 11
Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis.
Volk AE, Weishaupt JH, Andersen PM, et al.
Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V 2018; (30(2)):252-258 doi:10.1007/s11825-018-0185-3.
PMID: 30220791 - 12
Anterior Horn Cell Disease in Adulthood: Unmasking Spinal Muscular Atrophy Type 4.
Rafique S, Odeh A
Cureus 2026; (18(3)):e105356 doi:10.7759/cureus.105356.
PMID: 42005122 - 13
SMN1 Duplications Are Associated With Progressive Muscular Atrophy, but Not With Multifocal Motor Neuropathy and Primary Lateral Sclerosis.
Bos JW, Groen EJN, Wadman RI, et al.
Neurology. Genetics 2021; (7(4)):e598 doi:10.1212/NXG.0000000000000598.
PMID: 34169148 - 14
Pre-symptomatic diagnosis in ALS.
Corcia P, Lumbroso S, Cazeneuve C, et al.
Revue neurologique 2020; (176(3)):166-169 doi:10.1016/j.neurol.2019.07.027.
PMID: 31932031 - 15
Temporal course of cognitive and behavioural changes in motor neuron diseases.
McHutchison CA, Wuu J, McMillan CT, et al.
Journal of neurology, neurosurgery, and psychiatry 2024; (95(4)):316-324 doi:10.1136/jnnp-2023-331697.
PMID: 37827570 - 16
Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.
Talman P, Duong T, Vucic S, et al.
BMJ open 2016; (6(9)):e012054 doi:10.1136/bmjopen-2016-012054.
PMID: 27694488 - 17
Cognitive and behavioural changes in PLS and PMA:challenging the concept of restricted phenotypes.
de Vries BS, Rustemeijer LMM, Bakker LA, et al.
Journal of neurology, neurosurgery, and psychiatry 2019; (90(2)):141-147 doi:10.1136/jnnp-2018-318788.
PMID: 30076267 - 18
Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria.
Cortés-Vicente E, Pradas J, Marín-Lahoz J, et al.
Amyotrophic lateral sclerosis & frontotemporal degeneration 2017; (18(5-6)):333-340 doi:10.1080/21678421.2017.1316408.
PMID: 28440098
This page is for informational purposes only and does not constitute medical advice. Your neurologist and care team should interpret your EMG, MRI, and genetic results and decide which tests or follow-up are appropriate.